Where do you inject Ozempic for weight loss — and what the UK actually licenses

Semaglutide injections go into the fatty tissue just beneath the skin, abdomen, outer thigh, or upper arm are all suitable sites.
Rotating the site with each weekly injection reduces the risk of lumps, bruising or skin changes at a single spot.
Ozempic is licensed in the UK for type 2 diabetes; Wegovy (same active ingredient) is the licensed option for weight management.
Injection technique, site hygiene and storage should always follow the instructions in your medicine's Patient Information Leaflet and your prescriber's guidance.

Ozempic is injected subcutaneously into the abdomen, thigh, or upper arm, rotating the site each week to avoid skin irritation. Those are the standard injection locations for semaglutide. One thing worth knowing upfront, though: Ozempic is licensed in the UK for type 2 diabetes, not for weight loss. The medicine licensed for weight management is Wegovy, which contains the same active ingredient at a higher maintenance dose. If your search is really about semaglutide for weight loss, this page covers everything you need — injection sites, technique, and the correct licensed route.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

Injection sites, technique and the UK licensing picture for semaglutide

Which parts of the body can you inject semaglutide into?

Whether the medicine is Ozempic or Wegovy, semaglutide is given as a subcutaneous injection, meaning it goes into the layer of fat just under the skin, not into a muscle or a vein. The three approved sites are the abdomen (at least a few centimetres from the navel), the outer thigh, and the upper arm. All three are areas with enough fatty tissue to absorb the medicine steadily.

The abdomen tends to be the most convenient for self-injection because it is easy to see and reach. The outer thigh works well if you prefer to sit down while injecting. The upper arm is a viable choice, though some people find it harder to pinch the skin there without assistance.

Each site has a wide usable area, so you can vary the exact spot within it. Injecting into the same small patch repeatedly can cause lipohypertrophy, a small fatty lump under the skin that affects how the medicine is absorbed. Rotating properly sidesteps that. The best place to inject is ultimately the one you can reach comfortably and rotate consistently.

The NHS semaglutide medicines page has a clear overview of technique alongside its summary of the medicine; it is a good first read before your first injection.

Does the injection site affect how well semaglutide works?

Research into GLP-1 medicines generally shows that absorption is broadly similar across the three approved sites, so the primary reason to rotate is skin health rather than pharmacokinetic precision. What does affect the medicine's behaviour more noticeably is injecting into an area of existing scar tissue or a lipohypertrophy lump, absorption can be slower and less predictable there, which is one practical reason why rotation guidance exists in the first place.

Temperature matters too. Injecting a pen that has just come straight from the back of the fridge can feel more uncomfortable than one that has been at room temperature for the permitted window beforehand. The exact window varies by product, so the Patient Information Leaflet (not general advice online) is the source to follow for that detail.

Technique also plays a role. Pinching a small fold of skin before inserting the needle helps ensure the medicine reaches subcutaneous tissue rather than muscle, particularly at the thigh and arm. Most pre-filled pens used for semaglutide have a short, fine needle designed for subcutaneous use; there is no need to insert it at an angle unless the leaflet specifies otherwise. Cleaning the site beforehand is straightforward, alcohol swabs are commonly used for this and should be allowed to dry fully before injecting.

Ozempic is licensed for type 2 diabetes in the UK, so what should you use for weight loss?

This distinction matters and it comes up constantly. The mechanism behind semaglutide is the same regardless of brand name, but UK medicines licensing is product-specific. The MHRA licenses Ozempic for type 2 diabetes management. Wegovy, also semaglutide but at a 2.4 mg weekly maintenance dose (rising to 7.2 mg with the newer pen approved in April 2026), is the product licensed for weight management in adults.

NICE recommends Wegovy for weight management under specific criteria set out in NICE technology appraisal TA875. Privately, Wegovy is available to adults with a BMI of 30 or above, or 27 or above with at least one weight-related health condition, subject to a prescriber's clinical assessment. Tirzepatide (Mounjaro) is a second licensed option for weight management and is the only dual GIP and GLP-1 receptor agonist currently available in the UK.

If you are researching semaglutide injections specifically for weight loss, the right starting point is Wegovy, not Ozempic. Our weight-loss treatment overview sets out both options side by side.

What about injection frequency and the number of pens you need?

Semaglutide for weight management is a once-weekly injection, regardless of dose. The titration schedule means the dose increases gradually over several months, starting low to help the body adjust, then stepping up as your prescriber confirms you are tolerating it well. Injection frequency stays at once a week throughout; it is the dose, not the schedule, that changes.

In practical terms this means picking a day of the week that suits your routine and sticking to it. Many people find a morning that is already a bit structured (a weekend morning, or a weekday before the school run) easier to remember than a random evening. The injection itself takes under a minute once technique is established.

Sharps disposal is a small but real responsibility. A sharps container keeps used needles safe and out of household bins; your local pharmacy or GP surgery can advise on collection. How many injections you use overall depends on the length of your treatment, something a prescriber reviews with you at each stage. If you are considering whether Wegovy through a regulated UK pharmacy is the right route for you, starting a free consultation is the practical next step.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions